Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 8Cholangiocarcinoma 3Recurrence 2Leukemia 2Glioma 2Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1IDH1-Mutated Malignancies 1Hematologic Neoplasms 1Chondrosarcoma 1

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3durvalumab 3derazantinib 3Folfox protocol 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2fludarabine 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × ivosidenib × Clear all
NCT05876754 2026-02-19

ProvIDHe

Servier

Phase 3 Recruiting
220 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT02989857 2024-08-20

ClarIDHy

Servier

Phase 3 Completed
187 enrolled 34 charts 1 FDA
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡